Evaluation of Novel Fetal Hemoglobin Inducer Drugs in Treatment of β-Hemoglobinopathy Disorders
Open Access
- 1 January 2013
- journal article
- review article
- Vol. 7 (3) , 47-54
Abstract
The use of fetal hemoglobin (HbF) inducer drugs is considered as a novel approach in treatment of β-hemoglobinopathies, especially β- thalassemia and sickle cell disease. HbF inducers including hydroxyurea, histone deacetylase (HDAC) inhibitor agents such as sodium butyrate, azacitidine, decitabine and new immunomodulator drugs like pomalidomide, lenalidomide and thalidomide can reduce α-globin chain production in erythroid progenitors and improve α: β chain imbalance, the most crucial complication of β-thalassemia. In this article, we reviewed more than 40 articles published from 1979 to 2012 in the field of fetal hemoglobin augmentation. Recent studies suggest the synergistic effect of drug combinations in efficient induction of fetal hemoglobin and gene over-expression. It seems that drugs which act with different molecular and epigenetic mechanisms have proper synergistic effects in fetal hemoglobin induction and gene over-expression.Keywords
This publication has 55 references indexed in Scilit:
- Zinc finger nucleases for targeted mutagenesis and repair of the sickle-cell disease mutation: An in-silico studyBMC Hematology, 2012
- A pilot study of subcutaneous decitabine in β-thalassemia intermediaBlood, 2011
- The Ethanol Extract of Fructus trichosanthis Promotes Fetal Hemoglobin Production via p38 MAPK Activation and ERK Inactivation in K562 CellsEvidence-Based Complementary and Alternative Medicine, 2011
- Beta-thalassemiaOrphanet Journal of Rare Diseases, 2010
- The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic miceBlood, 2010
- Epigenetics of β-globin gene regulationMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008
- Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemiaProceedings of the National Academy of Sciences, 2008
- Pomalidomide and lenalidomide regulate erythropoiesis and fetal hemoglobin production in human CD34+ cellsJournal of Clinical Investigation, 2008
- Thalidomide induces γ-globin gene expression through increased reactive oxygen species–mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesisBlood, 2007
- Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves γ-globin activation by CREB1 and ATF-2Blood, 2006